Medicines and Healthcare products Regulatory Agency business plan published

The Medicines and Healthcare products Regulatory agency (MHRA) has today published their 2015/16 business plan.

The plan highlights the key areas they will focus on over the coming year. This includes:

  • supporting the cross-government innovation and growth agenda – including playing a key part in the Accelerated Access Review
  • implementing revised medical devices funding arrangements
  • driving forward work on key EU negotiations and implementation relating to clinical trials, falsified medicines and medical devices
  • continuing to grow the Clinical Practice Research Datalink (CPRD) and increase uptake of its services
  • building closer and strong collaboration with the Department of Health and partners in the health and care system, ensuring that they are working towards common goals around public health and innovation and growth
  • progressing the agency’s efficiency programme
  • being at the leading edge of digital devices and technology
  • developing further their excellence in science, including developing the capabilities of the National Institute for Biological Standards and Control (NIBSC) to ensure it remains a global leader in standardisation and control of biological medicines
  • leading the further development of incident and safety reporting systems – including embedding Yellow Card reporting into the National Health Service (NHS) and care system
  • continuing to meet their aspiration as a world-class regulator that leads the way in best practice

The full document can be found here.

Published on 30. June 2015 in News UK